📊 SHPH Key Takeaways
Is Shuttle Pharmaceuticals Holdings, Inc. (SHPH) a Good Investment?
Shuttle Pharmaceuticals faces an acute existential liquidity crisis with approximately 2-3 months of cash runway at current burn rates ($2.4M operating cash burn against only $100K annual revenue), indicating either a pre-clinical/failed program or severely distressed operations. Without immediate substantial capital infusion, the company poses extreme bankruptcy and shareholder dilution risk, with negative operating margins of -2216.8% demonstrating fundamental business model failure.
Shuttle Pharmaceuticals Holdings, Inc. Key Strengths (SHPH)
- Minimal long-term debt burden of $426.2K reduces creditor pressure
- Moderate debt-to-equity ratio of 0.13x provides some financial flexibility relative to equity base
- Asset base of $11.8M provides potential liquidation value
SHPH Stock Risks: Shuttle Pharmaceuticals Holdings, Inc. Investment Risks
- Critical liquidity crisis: current ratio of 0.30x indicates inability to cover short-term obligations
- Catastrophic cash burn: $2.4M operating cash outflow against $100K revenue represents only 2-3 months of remaining runway
- Existential solvency risk: negative operating margins of -2216.8% and -64.3% ROE indicate fundamental business failure or inadequately financed pre-clinical stage
- Zero insider Form 4 filings in 90 days suggests complete lack of management confidence
- Non-viable unit economics: negative FCF margin of -2436.4% with stagnant revenue growth
Key Metrics to Watch
- Monthly cash burn rate and remaining runway - determines bankruptcy timeline
- Revenue trajectory and path to operating profitability - only fundamental metric that matters for survival
- Capital raise announcements (equity/debt) - sole mechanism to extend solvency without operational turnaround
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SHPH Profit Margin, ROE & Profitability Analysis
SHPH vs Healthcare Sector: How Shuttle Pharmaceuticals Holdings, Inc. Compares
How Shuttle Pharmaceuticals Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Shuttle Pharmaceuticals Holdings, Inc. Stock Overvalued? SHPH Valuation Analysis 2026
Based on fundamental analysis, Shuttle Pharmaceuticals Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Shuttle Pharmaceuticals Holdings, Inc. Balance Sheet: SHPH Debt, Cash & Liquidity
SHPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Shuttle Pharmaceuticals Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-82.60 indicates the company is currently unprofitable.
SHPH Revenue Growth, EPS Growth & YoY Performance
Shuttle Pharmaceuticals Holdings, Inc. Dividends, Buybacks & Capital Allocation
SHPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Shuttle Pharmaceuticals Holdings, Inc. (CIK: 0001757499)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SHPH
What is the AI rating for SHPH?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SHPH's key strengths?
Claude: Minimal long-term debt burden of $426.2K reduces creditor pressure. Moderate debt-to-equity ratio of 0.13x provides some financial flexibility relative to equity base.
What are the risks of investing in SHPH?
Claude: Critical liquidity crisis: current ratio of 0.30x indicates inability to cover short-term obligations. Catastrophic cash burn: $2.4M operating cash outflow against $100K revenue represents only 2-3 months of remaining runway.
What is SHPH's revenue and growth?
Shuttle Pharmaceuticals Holdings, Inc. reported revenue of $100.0K.
Does SHPH pay dividends?
Shuttle Pharmaceuticals Holdings, Inc. does not currently pay dividends.
Where can I find SHPH SEC filings?
Official SEC filings for Shuttle Pharmaceuticals Holdings, Inc. (CIK: 0001757499) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SHPH's EPS?
Shuttle Pharmaceuticals Holdings, Inc. has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SHPH's fundamental grade?
Based on our AI fundamental analysis in June 2026, Shuttle Pharmaceuticals Holdings, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SHPH stock overvalued or undervalued?
Valuation metrics for SHPH: ROE of -64.3% (sector avg: 15%), net margin of -2,152.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SHPH's AI grade for 2026?
Our dual AI analysis gives Shuttle Pharmaceuticals Holdings, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SHPH's free cash flow?
Shuttle Pharmaceuticals Holdings, Inc.'s operating cash flow is $-2.4M, with capital expenditures of $19.0K. FCF margin is -2,436.4%.
How does SHPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,152.5% (avg: 12%), ROE -64.3% (avg: 15%), current ratio 0.30 (avg: 2).